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OBJECTIVE: Quantify Crohn’s disease (CD) patients’ maximum
acceptable risk (MAR) of treatment-related serious adverse
events (SAE) for improvements in daily symptom experience.
METHODS: An on-line panel of self-identiﬁed CD patients com-
pleted a series of choice-format conjoint tradeoff tasks. Patients
selected between treatment alternatives with varying efﬁcacy and
risk levels. The treatment attributes included the daily symptom
severity and activity limitations, the potential for serious 
complications (ﬁstulas, abscesses, bowel obstructions), the time
between ﬂare-ups, oral steroid use and varying levels of SAE
risks, including progressive multifocal encephalopathy (PML)
death or disability, and death from serious infection or lym-
phoma. The questionnaire also contained items regarding demo-
graphics, disease and treatment history, and the short form of
the Inﬂammatory Bowel Disease Questionnaire (SIBDQ). The
maximum acceptable 10-year MAR was calculated for various
clinical beneﬁt levels. RESULTS: A total of 357 patients com-
pleted the survey. Improvements in daily symptom severity were
the most important factor in treatment preferences. Higher MAR
(greater risk acceptance) was observed for trade-off tasks involv-
ing higher levels of clinical beneﬁt, patients with lower SIBDQ
scores, and patients reporting a low level of worry about SAEs.
For the PML SAE, mean MARs (SD) for an improvement from
severe daily symptoms to remission and moderate daily symp-
toms to remission were 7.2% (0.26) and 4.7% (0.18), respec-
tively. The lowest observed MAR for any of the three studied
SAEs is well above the observed rates of SAE occurrence with
natalizumab or any of the commonly used CD medications.
CONCLUSIONS: Medical interventions carry risks of adverse
outcomes that must be evaluated against their clinical beneﬁts.
CD patients indicated they are willing to accept a deﬁned risk 
of death or disability in exchange for clinical efﬁcacy. The 
patient perspective on the balance between potential beneﬁts 
and risks can assist in making treatment and regulatory 
decisions.
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Erectile dysfunction (ED) affects approximately 10 million men
in the US. ED has been associated with cardiovascular risk
factors and depression in a managed care setting. However,
similar data among Medicaid recipients is limited. OBJECTIVE:
To estimate the excess prevalence of selected comorbidities in
men diagnosed with ED in the California Medicaid (Medi-Cal)
program. METHODS: This study employed a retrospective
cross-sectional matched cohort design and administrative claims
data for a 20% random sample of Medi-Cal recipients. Men
selected were 18+ years of age, had a diagnosis of ED (ICD-9-
CM 302.72, 607.84), or were dispensed a PDE5 inhibitor (i.e.,
sildenaﬁl, tadalaﬁl, vardenaﬁl) between July 1, 2001 and June
30, 2002 (“study period”), and were eligible for non-capitated
Medicaid-only coverage during the study period. The compari-
son cohort consisted of patients without ED and not dispensed
a PDE5 inhibitor, matched on age, gender, and race. The excess
prevalence of selected comorbidities was estimated as the ratio
of proportions between the ED and comparison cohorts.
RESULTS: A total of 332 patients with ED met study inclusion
criteria. ED patients and their matched controls (n = 332) aver-
aged 52 years of age; 43% were white, 18% were Asian, and
18% were African-American. Relative to matched controls, ED
patients were 67% more likely to be diagnosed with hyperten-
sion, 74% more likely to be diagnosed or treated for dyslipi-
demia, 84% more likely to be diagnosed or treated for diabetes,
and 153% more likely to be diagnosed with depression. ED
patients (versus matched controls) were about two-thirds more
likely to have at least one of the four conditions listed above
during the study period. Prostate cancer also was 9.5 times as
likely among ED patients. CONCLUSION: There appears to be
higher rates of prevalence of hypertension, dyslipidemia, dia-
betes, depression, and prostate cancer among ED patients in the
Medi-Cal program.
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OBJECTIVE: To estimate cost-effectiveness of carbetocine com-
pared to oxytocin in preventing uterine atony in patients with
risk factors. METHODS: A randomized pragmatic clinical trial
in patients with risk factors for uterine atony was performed in
the Instituto Mexicano del Seguro Social (IMSS) in Mexico City.
Two therapies were included: carbeteocine and oxytocin. One
hundred patients with fetal macrosomia, polyhydramnios, low
insertion of the placenta, multiple gestation, prolonged labor,
uterine myomas and chorioamnionitis were included in each
group. The effectiveness was deﬁned as the reduction of the
number of patients with uterine atony. The use of resources was
obtained from the clinical trial and the costs were gotten from
ﬁnancial information from IMSS, and are expressed in US 2006
dollars. Univariate and probabilistic sensitivity analyses were
performed using Monte Carlo simulation. RESULTS: No statis-
tically signiﬁcant difference was found in general characteristics,
obstetric background and risk factors distribution in both
groups. Uterine atony was reported in 20% in the oxytocin
group compared to 5% in the carbetocine one (p < 0.0001). Mul-
tiple gestation and fetal macrosomia were the most frequent
diagnosis, 30% (p < 0.0001). Bleeding was less than 500mL in
the carbetocine group and 500 to 1000mL in the oxytocin one
(p < 0.0001). Mean cost per patient treated with carbetocine 
was $3468 vs. $4082 for oxytocine (p < 0.0001). Mean cost-
effectiveness ratio for oxytocin was $5103, while for carbetocine
$3651; ICER showed that carbetocine was dominant. Univari-
ate analysis supported those results. A Monte Carlo microsimu-
lation with 10,000 iterations was performed using probability
distribution data from the clinical trial. The acceptability curve
and health net beneﬁts showed that carbetocine group was supe-
rior independently of WTP. CI 99% by ellipse method showed
that carbetocine was dominant in 100% of cases. CONCLU-
SIONS: Carbetocine was the most cost-effective drug to prevent
uterine atony in patients with risk factors.
